[Impact of the obesity on the use of antipsychotic drugs in adult population attended in several primary care centers].
BACKGROUND
We describe the association between the obesity and the use of antipsychotic drug (APD) in patients attended by five primary care teams.


METHODS
Multicenter-retrospective design, carried out between July 2004 and June 2005, in patients who consumed APD treatment. A Body Mass Index (BMI) >29 kg/m2 was considered obesity. The main measurements were: consumption of APD, generals (gender and age), comorbidities and clinical parameters. Regression logistic analysis and ANCOVA (Bonferroni-adjustment) were applied to correct the model.


RESULTS
From a total of 42,437 attended patients (mean age: 50.9 (SD: 17.8) years; women: 59.9 %; with obesity: 27.3% [confidence interval [CI] of 95 %: 26.9- 27.7]), the 1.3% received APD treatment (typical: 48.8%; atypical: 51.2%; p=not significant). In the logistic-model the obesity was related with the ADP use (odds ratio [OR]: 1.5; CI: 1.3-1.8), hypertension (OR: 2.4; CI:2.2-2.5), diabetes (OR: 1.4; CI: 1.3-1.5) and dyslipidemia (OR: 1.3; CI: 1.2-1.4); p=0,000. The adjusted BMI, in presence of APD, was 27.8 kg/m2 vs. 27.4 kg/m2; p=0,002.


CONCLUSIONS
Obesity was associated with the use of APD and with the presence of hypertension, diabetes and dyslipidemia. Differences could not be observed between the use of typical or atypical APD.
Sicras-Mainar
A
A
Planning Administration, Badalona Serveis Assistencials, Badalona, Barcelona, Spain. asicras@bsa.gs <asicras@bsa.gs>
Rejas-Gutiérrez
J
J
Navarro-Artieda
R
R
Blanca-Tamayo
M
M
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000453:epidemiology*; D011320:Primary Health Care; D012189:Retrospective Studies
D014150:Antipsychotic Agents